| 영문 | antianginal drug | 한글 | 항협심증제 |
|---|---|---|---|
| 설명 | 협심증은 심장동맥의 혈류를 좋게하거나 심장이 혈류에 비해서 많은 일을 하는 것을 억제함으로써 치료될 수 있다. ① nitrate계통의 약물: 혈관을 이완시키는 작용을 함으로써 심장동맥의 혈류를 좋게 한다. ② 칼슘통로차단제(verapamil, nifedipine): 모든 근육의 수축에는 Ca이 관여한다. 즉 Ca이 있어야만 근육의 수축이 가능해진다. 그러므로 Ca이 세포속으로 들어가는 것을 억제하는 약제는 근육의 수축을 막는다. 이 약은 심장의 근육에 작용하여 심장 근육의 수축을 억제하며 심장이 과도하게 일하는 것을 막고, 또 심장동맥의 수축에 관여하는 근육에 작용을 하여 심장동맥을 이완시켜서 혈류를 좋게 한다. ③ 베타차단제(beta-blocker): 신체의 운동량이나 기타의 요구에 의해서 심장을 빨리 뛰게하는 신경은 바로 베타-교감신경이다. 교감신경계란 사람이 위급한 상황에서 작용하는 자율신경계이다. 즉 사람이 긴장하거나 싸울 경우에 전형적으로 교감신경계가 작용한다. 즉 심장이 뛰거나 소화가 않되거나 동공이 커지는 것 따위가 바로 교감신경계의 역할이라고 할 수 있다. 이 교감신경계에서 말초장기에 보내는 신경이 교감신경이다. 그러므로 심장에서 심장을 신체에 필요에 따라서 많은 일을 하게하는 신경을 차단할 경우에는 협심증을 치료할 수 있게 된다(심장의 산소나 기타 영양분의 수요를 줄인다). |
||
| PFU | plaque-forming unit; pock-forming unit |
|---|---|
| CD | cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise... |
| DAST | drug abuse screening test; drug and alcohol screening test |
| DD | dangerous drug; data definition; day of delivery; degenerated disc; degenerative disease; delusional... |
| DI | date of injury; defective interfering [particle]; dentinogenesis imperfecta; deoxyribonucleic acid i... |
| plaque-forming unit | <virology> Number of infectious virus particles or Ig producing cells per unit volume. See: plaque assay. <microbiology> Refers to any entity which can give rise to a plaque. For example: if a phage stock solution has 1010 pfu/ml, it means that every ml of this stock has 1010 phage particles which can form plaques. This (pfu/ml) is the conventional way to refer the concentration of a phage preparation. Compare: CFU. (10 Oct 1997) |
|---|---|
| spleen focus-forming viruses | Murine leukaemia viruses that are replication-defective and rapidly transforming. The envelope gene plays an essential role in initiating erythroleukaemia, manifested by splenic foci, splenomegaly, and polycythemia. Spleen focus-forming viruses are generated by recombination with other viral types including friend p (polycythemia), friend a (anaemia), rauscher, and cas (from wild mice at lake casita, california). (12 Dec 1998) |
| endospore-forming bacteria | A group of rods or cocci whose taxonomic affinities are uncertain. They form endospores, thick-walled bodies formed within the vegetative cells of certain bacteria, able to withstand adverse environmental conditions for prolonged periods. (12 Dec 1998) |
| focus-forming assay | <investigation> A lab technique used to find out if a particular piece of DNA contains oncogenes (genes which are associated with cancer). This is done by putting the DNA into animal cells which normally show contact inhibition, or which stop growing when they come into physical contact with other cells or reach a certain density in the culture. If the cells lose contact inhibition and form areas of densely-packed cells (called foci) after receiving the DNA, it means that the DNA did contain oncogenes. (05 Jan 1997) |
| focus-forming unit | A measurement of the concentration of live virus in a given amount of fluid. This is measured by spreading a known amount of the fluid over a layer of cultured cells which are infected by the virus, then counting the number of areas in the culture which look infected. (09 Oct 1997) |
| forming face | The side of the Golgi apparatus which faces the rough endoplasmic reticulum, where vesicles budding off of the rough endoplasmic reticulum fuse to the Golgi apparatus. Also called the cis side of the Golgi apparatus. (09 Oct 1997) |
| Friend spleen focus forming virus | <virology> Defective virus found in certain strains of Friend virus, detected by its ability to form foci in spleens of mice and believed to be responsible in those strains for the production of a leukaemia associated with polycythaemia rather than anaemia. (18 Nov 1997) |
| lignin-forming peroxidase | <enzyme> Involved in polymerization of cinnamyl alcohols into lignin;amino acid sequence has been determined for tobacco enzyme Registry number: EC 1.11.1.- (26 Jun 1999) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| akathisia, drug-induced | Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation). (12 Dec 1998) |
| antineoplastic drug | A drug that stops or slows the maturation and spread of tumour cells (benign or malignant). (09 Oct 1997) |
| maintenance drug therapy | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |